We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 13, 2021

HER2 BATs Consolidation Therapy for HER2− Metastatic Breast Cancer

Journal for immunotherapy of cancer

 

Additional Info

Journal for immunotherapy of cancer
Phase II Clinical Trial Using Anti-CD3 × Anti-HER2 Bispecific Antibody Armed Activated T Cells (HER2 BATs) Consolidation Therapy for HER2 Negative (0-2+) Metastatic Breast Cancer
J Immunother Cancer 2021 Jun 01;9(6)1-12, LG Lum, Z Al-Kadhimi, A Deol, V Kondadasula, D Schalk, E Tomashewski, P Steele, K Fields, M Giroux, Q Liu, L Flaherty, M Simon, A Thakur

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading